To investigate the effect of baohuoside-I against nasopharyngeal carcinoma (NPC) and its underlying mechanism, baohuoside-I was employed to treat NPC cell lines CNE1 and CNE2 in vitro, followed by attachment and detachment assays to evalute the epithelial-mesenchymal transition (EMT) phenotype markers. Baohuoside-I was also administered to experimental mice to assess its effect on xenograft tumor growth and NPC cell metastasis. A microRNA (miRNA, miR) microarray was performed to screen for miRNA altered by baohuoside-I in NPC cells. Bioinformatic tools and luciferase activity assay was conducted to identify the downstream molecules mediating the anti-tumor property of baohuoside-I. Baohuoside-I inhibited EMT and metastasis and upregulated miR-370-3p in NPC cells, which was shown to directly recognize and inhibit expression of Hedgehog pathway component Smoothened (SMO). Baohuoside-I suppresses metastasis as well as EMT of NPC cells through targeting the Hedgehog pathway component SMO, and may serve as a potent anti-tumor agent in the clinical management of NPC.

为了研究保活苷-I对鼻咽癌（NPC）的作用及其潜在机制，使用保活苷-I在体外治疗鼻咽癌细胞系CNE1和CNE2，然后进行附着和脱离测定以评估上皮-间质转化（EMT） ) 表型标记。宝火苷-I 也用于实验小鼠，以评估其对异种移植肿瘤生长和 NPC 细胞转移的影响。进行微RNA（miRNA，miR）微阵列以筛选NPC细胞中被保活苷-I改变的miRNA。进行生物信息学工具和荧光素酶活性测定以鉴定介导保火苷-I抗肿瘤特性的下游分子。保火苷-I 抑制 EMT 和转移并上调 NPC 细胞中的 miR-370-3p，它被证明可以直接识别和抑制 Hedgehog 通路组件 Smoothened (SMO) 的表达。保火苷-I 通过靶向 Hedgehog 通路组分 SMO 抑制 NPC 细胞的转移和 EMT，并可作为 NPC 临床治疗中的有效抗肿瘤剂。